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Endogenous Fibroblast Growth Factor 2 is Cardioprotective in an In Vivo, Closed-Chest, Murine 
Model of Regional Cardiac Ischemia-Reperfusion Injury 
Stacey House MD PhD, Carla Weinheimer MS, Attila Kovacs MD, and David Ornitz MD PhD 
Washington University in St. Louis School of Medicine, St. Louis, Missouri 
Fibroblast growth factor 2 (FGF2) has been shown to be cardioprotective in ex vivo and chronic ischemia 
models.  Limited data is available on the ability of FGF2 to protect the heart from ischemia-reperfusion 
injury in vivo.  We have utilized a clinically relevant, in vivo, closed-chest model of regional cardiac 
ischemia-reperfusion (IR) injury.  Mice with a targeted ablation of the Fgf2 gene (Fgf2-/-) and wildtype 
controls were subjected to 90 minutes of occlusion of the left anterior descending artery followed by 
reperfusion for 7 days.  Fgf2-/- mice do not show any baseline abnormalities in cardiac morphometry or 
function.  When subjected to closed-chest, regional cardiac IR injury, Fgf2-/- mice have significantly 
increased myocardial infarct size as measured by echocardiography compared to wildtype mice at both 1 
day and 7 days post-IR injury (p<0.05).  In addition, Fgf2-/- mice show significantly worsened cardiac 
function at 1 day and 7 days post-IR injury (p<0.05).  Scar length, detected by trichrome and picosirius 
red staining, is significantly increased in Fgf2-/- hearts (p<0.05). Myocyte cross-sectional area 
measurement shows an impaired cardiac hypertrophic response in the Fgf2-/- hearts in the peri-infarct 
area (p<0.05) but not in remote myocardium.  Fgf2-/- mice have normal vessel density compared to 
wildtype controls in the non-injured state, but after cardiac IR injury, Fgf2-/- hearts showed significantly 
decreased vessel density (both capillaries and smooth muscle actin containing vessels) in the peri-infarct 
area compared to wildtype controls (p<0.05), suggesting a defect in vascular remodeling in the Fgf2-/- 
mice after IR injury.  Endogenous FGF2 improves cardiac function, reduces myocardial infarct size, and 
mediates cardiomyocyte hypertrophy and vascular remodeling after cardiac IR injury.  These data show 
the cardioprotective potential of endogenous FGF2 in a clinically-relevant, in vivo, closed-chest, regional 
cardiac ischemia-reperfusion model which mimics acute myocardial infarction.    
 
